Articles On Bionomics (ASX:BNO)

Summary The S&P/ASX200 traded up by 12.60 points or 0.17% at 7,327.60 by Tuesday afternoon. All the “big four” banks were trading higher ahead of the monetary policy announcement by the Reserve Bank. The energy sector was the best...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Bionomics (ASX:BNO) has announced it will proceed with evaluating its lead clinical compound, BNC210, for the treatment of acute treatment of Social Anxiety Disorder while progressing toward the start of its planned Phase 2b trial i...

Rapid oral absorption of BNC210 novel tablet formulation ideally suited for acute treatment of anxiety in patients with Social Anxiety Disorder BNC210 Phase 2b PTSD trial on target for start in mid-2021 with U.S. CRO Premier Research sele...

Summary Biopharmaceutical company Bionomics Limited will expand its product pipeline for the treatment of Social Anxiety Disorder (SAD). The Company disclosed that the rapid oral absorption of the novel tablet formulation of BNC210 is...

Wall Street dropped on Friday, but still positive in April On Friday trading, the Dow Jones fell 0.54%, S&P 500 was down 0.72%, while tech heavy NASDAQ also dropped 0.85%. But the market was still able to hold on to its monthly gains, w...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

Summary Australian players MGC Pharmaceuticals and ArchTIS limited were under the spotlight following recent crucial developments. Biopharma player MGC Pharma announced the acquisition of MediCaNL that is likely to deliver cost savings...

If you want to know which ASX stocks fund managers and famous investors are putting their money into we’ve been keeping track of substantial holder buys (and sells). Trading Places is Stockhead’s recap of the substantial holder movements am...

ADELAIDE, Australia, April 9, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics) has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on 8 March 2021 (Entitlement Offer) and concurr...

Source: wutzkohphoto, Shutterstock Today, the Australian market traded in the green. The benchmark index ASX 200 initially spiked, and after gaining significant points, it fell sharply towards the afternoon but later on bounced back on the...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

2021 is set to be another big year for ASX capital raisings with solid volumes so far in 2021. In the first nine weeks of the new year, ASX companies have raised over $1.96 billion. Although this is lower than the $3 billion raised in the f...

The Bionomics Ltd (ASX: BNO) share price is in positive territory today after announcing a non-renounceable entitlement offer. During mid-afternoon trade, the clinical-stage biopharmaceutical company’s shares are up 3.5% to 30 cents. This...

In February, ASX fintech stocks were winners, losers and winners again. The benchmark ASX 200 index made a 1 per cent gain for month – despite a late month drop — driven largely by favourite fintech Zip (ASX:Z1P) +43%, as well as Virgin Mon...

Source: ShutterstockProfessional Summary Biotech penny stocks are extremely volatile, given the unpredictable nature of the biotechnology industry. Positive clinical developments and regulatory approvals for biotech penny players coul...

BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase 2b PTSD trial BNC210 Phase 2b PTSD trial on target for start in mid-2021 with final dose selected ADELAIDE, Australia, F...

It’s been a dismal day for the market, although small-cap investors can perhaps take some measure of solace knowing that the minnows weren’t as badly hit as the market titans. The Small Ordinaries closed Friday down 37.6 points, or 1.18 per...

Bionomics (ASX:BNO) has announced a Memorandum of Understanding with EmpathBio, the wholly-owned subsidiary of German-based CNS clinical development company atai Life Sciences.

ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5) (Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly...

Commitments received for a placement of A$15,991,634 at A$0.145 per share Significant participation from North American and European institutional and sophisticated investors This capital raising enables proceeding with the Phase 2b PT...

The Bionomics Ltd (ASX: BNO) share price continues to climb today after the company announced it had received commitments for a placement. At the time of writing, shares in the clinical-stage biopharmaceutical company are up 2.2% to 22.5 c...

Clinical-stage biopharmaceutical company Bionomics (ASX:BNO) has announced that all patients have completed their treatment phase in the MODULATE clinical trial.

The MODULATE trial is evaluating new experimental approaches to immunotherapy treatment in colorectal cancer patients.

The company’s lead drug candidate BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor.

Summary Bionomics initiates a 7-day, twice-daily dosing pharmacokinetic clinical trial. The company’s leading candidate, BNC210, would be used with a new solid dose tablet formulation on the volunteers. The result from the trial is ex...

Adelaide’s Carina Biotech has announced an agreement to create CAR-T cells targeted at a cancer stem cell marker that is abundant in solid tumours.

The Bionomics Ltd (ASX: BNO) share price has run higher today after the company announced it has entered an agreement to licence its oncology drug candidate, BNC101, to Carina Biotech. At the market’s close, the Bionomics share price had s...

Bionomics (ASX:BNO) has announced the successful completion of the institutional component of its one for 12.54 pro-rata accelerated non‐renounceable entitlement offer.

A quick wrap of the ASX’s key winners and losers on Friday, August 28. Data is taken after the market closes at 4pm AEST. Stocks highlighted in yellow made potentially market-moving announcements during the day. Today 585 stocks rose, 813 d...

A quick wrap of the ASX’s key winners and losers on Thursday, August 27. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. Today 760 stocks rose, 634 declined and...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

A quick wrap of the key winners and losers on Tuesday, June 2. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made potentially market-moving announcements during the day.   Code Name Price % Chg...

The Bionomics Ltd (ASX: BNO) share price is charging higher today, up 16.67% at the time of writing on the back of a subscription agreement announcement. Bionomics is a clinical-stage biopharmaceutical company that develops treatments for...

We know that gambling dens aren’t open in these days of social distancing, but metaphorically speaking Paradigm Pharmaceuticals (ASX:PAR) is plonking it all on the black in terms of its “ballsy” pursuit of US approval for its drug for osteo...

Bionomics (ASX: BIO) has published data regarding its phase 2a trial into using its BNC210 drug to treat generalised anxiety disorder (GAD) patients. The company’s paper Cholinergic Modulation of Disorder-Relevant Neural Circuits in General...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

So the pot sector around the world is down and you’ve lost $$$. Maybe the way to dig your way out is to invest in… illegal drugs? Last week MindMed listed on Canada’s NSX-like NEO Exchange, raising $C24m ($27m) to sell curious dreams and we...

Clinical stage biopharmaceutical company Bionomics (ASX: BNO) has completed the sale of two wholly-owned subsidiaries to French company Domain Therapeutics for €1.79 million (A$3.04 million). The subsidiaries, Neurofit SAS and Prestwick Che...

Bionomics (ASX:BNO), a clinical-stage company leveraging proprietary platform technologies to discover and develop a pipeline of novel drug candidates targeting ion channels, has announced the sale of its French subsidiaries.

Bionomics Limited (ASX: BNO) a global clinical stage biopharmaceutical company, has accepted an offer from Domain Therapeutics to sell its two wholly owned subsidiaries, PC SAS and Neurofit SAS. Bionomics has an intercompany debt of €1.8...

Health care industry is one of the world’s fastest-growing industries, providing services to treat patients with preventive, curative and palliative care. The industry includes pharmaceutical & biotech companies, medical device producer...

The Bionomics Ltd (ASX: BNO) share price has been on fire on Monday morning. The clinical stage biopharmaceutical company’s shares rocketed over 43% higher to 13.5 cents in early trade. They have since dropped back a touch but are still up...

Clinical stage biopharma company Bionomics (ASX: BNO) is celebrating this morning after being granted “fast track designation” for its BNC210 development program for the treatment of post-traumatic stress disorder (PTSD) by the US Food and...